The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
To borrow from Winston Churchill, Aurobindo Pharma is a riddle, wrapped in a mystery, inside an enigma.
Back in August 2020, the Hyderabad-based company’s stock hit a 10-year high after it dethroned Sun Pharma as the top pharmaceuticals supplier to the lucrative US market. The 2020-21 fiscal was its best ever in terms of profits—at Rs 5,344 crore. We wrote about it here.
At that point, it seemed Aurobindo Pharma couldn’t put a foot wrong. Except it did.
A lot of its good tidings had to do with the US Food and Drug Administration largely clearing it of wrongdoing …
Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.
Executive Editor
surendar@mailtmc.com
Mumbai